Table 2. MGMT activity (fmol μg−1 DNA) in extracts of tumour samples from patients in the treatment groups indicated and as described in the Patients and Methods section.
| Sampling time | LM/TMZ, 40 mg/daya | LM/TMZ, 60–80 mg/daya | TMZ alone |
|---|---|---|---|
| Day 5 | |||
| N | — | 4 | 2 |
| Mean | — | 0 | 1.38 |
| Range | — | — | 0–2.8 |
| Day 6 | |||
| N | 6 | 6 | 2 |
| Mean | 0.64 | 2.79 | 1.23 |
| Range | 0–1.6 | 0–6.1 | 0–2.5 |
| Day 7 | |||
| N | 2 | 1 | 1 |
| Mean | 0.4 | 5.6 | 0 |
| Range | 0–0.8 | — | — |
| Day 8 | |||
| N | 1 | — | — |
| Value | 4.5 | — | — |
Abbreviations: LM=lomeguatrib; TMZ=temozolomide.
a
Treated first line or after progression on TMZ alone.